These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 24436960)

  • 1. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?
    Thomas RE; Spragins W; Lorenzetti DL
    Vaccine; 2013 Dec; 31(52):6201-9. PubMed ID: 24436960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yellow fever vaccine-associated viscerotropic disease: current perspectives.
    Thomas RE
    Drug Des Devel Ther; 2016; 10():3345-3353. PubMed ID: 27784992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
    Rafferty E; Duclos P; Yactayo S; Schuster M
    Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event reports following yellow fever vaccination, 2007-13.
    Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinician's perspective on yellow fever vaccine-associated neurotropic disease.
    Lecomte E; Laureys G; Verbeke F; Domingo Carrasco C; Van Esbroeck M; Huits R
    J Travel Med; 2020 Nov; 27(7):. PubMed ID: 32965473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
    Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
    Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of the yellow fever vaccine Stamaril®: a 17-year review.
    Cottin P; Niedrig M; Domingo C
    Expert Rev Vaccines; 2013 Nov; 12(11):1351-68. PubMed ID: 24066727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report.
    Volkov L; Grard G; Bollaert PE; Durand GA; Cravoisy A; Conrad M; Nace L; Courte G; Marnai R; Leparc-Goffart I; Gibot S
    BMC Infect Dis; 2020 Feb; 20(1):116. PubMed ID: 32041533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Am J Trop Med Hyg; 2012 Feb; 86(2):359-72. PubMed ID: 22302874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yellow fever vaccine for patients with HIV infection.
    Barte H; Horvath TH; Rutherford GW
    Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of 17D derived yellow fever vaccines.
    Domingo C; Niedrig M
    Expert Opin Drug Saf; 2009 Mar; 8(2):211-21. PubMed ID: 19309249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.